The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

In general, insulins used in children are rapid-acting insulin analogs, short-acting insulin, intermediate-acting insulin (NPH and Lente), and long-acting insulin analogs. These insulins are used ...

In a week marked by volatility, global markets faced renewed tariff threats and rising Treasury yields, causing major indices to decline. Amid these fluctuations, the resilience of growth companies ...

Demographic trends are strengthened by a market shift from human insulin toward modern insulin analogs (Novo's Levemir and NovoLog), next-generation insulin analogs (Tresiba, Fiasp), and a novel ...

Icodec is a basal insulin analog intended for once-weekly administration. However, the effect of age, ethnicity, and race on its treatment response remains unclear. [T]he efficacy and hypoglycemia ...

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

Bengaluru: Biocon Limited, a global biopharmaceutical company, has announced that the company has received approval in India ...

In today’s hyper-connected healthcare environment, the supply chain has quietly become one of the sector’s most vulnerable ...